A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy

Karissa L. Gable; Stojan Peric; Michael W. Lutz; Ivo Bozovic; Milutin Petrovic; Aleksandar Stojanov; Ivana Basta; Jeffrey A. Allen

doi:10.1002/brb3.2712

A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy

Karissa L. Gable, Stojan Peric, Michael W. Lutz, Ivo Bozovic, Milutin Petrovic, Aleksandar Stojanov, Ivana Basta, Jeffrey A. Allen

Neurology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

BACKGROUND AND AIMS: Fatigue is a common but poorly understood complaint in patients with immune-mediated polyneuropathies. We sought to evaluate changes in fatigue over 1 year in a cohort of chronic inflammatory demyelinating polyneuropathy (CIDP) patients and to correlate changes in fatigue with changes in disability and quality of life. Investigation into other factors that may contribute to fatigue with a particular interest in the role other chronic disease states may play was also performed.

METHODS: Fifty patients with CIDP who satisfied the 2010 EFNS/PNS diagnostic criteria were followed over the period of 1 year at three tertiary care centers in Serbia. Assessments of disability, quality of life, and patient perception of change and fatigue were collected at two time points 12 months apart. Comorbidities, treatment regimens, and sedating medication use was collected.

RESULTS: Disability, quality of life, and patient perception of change showed statistically significant correlations with change in fatigue (p < .01). Increased levels of fatigue were noted in patients who used sedating medications (p = .05) and who had a comorbid chronic medical condition (p = .01).

INTERPRETATION: Worsening fatigue correlates over time with increased disability and worse quality of life. Fatigue is not specific to CIDP, but is common in many chronic medical conditions and with the use of sedating medications. Our findings support the importance of identifying and supportively managing fatigue in patients with CIDP, but cautions against considering fatigue as a CIDP diagnostic symptom or using fatigue to justify immunotherapy utilization.

Original language	English (US)
Article number	e2712
Journal	Brain and Behavior
Volume	12
Issue number	8
DOIs	https://doi.org/10.1002/brb3.2712
State	Published - Aug 2022

Bibliographical note

Funding Information:
K. G. was a consultant for Apellis and Medscape. J. A. is a consultant for Argenx, alexion, annexon, Akcea, CSL behring, Johnson & Johnson, Grifols, Sanofi, Takeda. S. P. reports the following: he has received lecture honoraria from Pfizer, Viatris, Teva Actavis, Berlin Chemie Menarini, Mylan, Worwag, Adoc and Salveo; research grants from Kedrion, Octapharma and Argenx; consultant fees from Argenx, Mylan and Roche; and travel grants from Octapharma, Kedrion, Teva Actavis, Sanofi Genzyme, Pfizer, Roche, Adoc and Berlin Chemie Menarini. The remaining authors have no disclosures to report.

Publisher Copyright:
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.

Keywords

chronic inflammatory demyelinating polyneuropathy
fatigue
quality of life
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/complications
Polyneuropathies
Humans
Quality of Life
Fatigue/diagnosis
Chronic Disease

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1002/brb3.2712

Find It

Find It at U of M Libraries

Cite this

@article{2e89e23f0a8c40e7964c357d17145be8,

title = "A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy",

abstract = "BACKGROUND AND AIMS: Fatigue is a common but poorly understood complaint in patients with immune-mediated polyneuropathies. We sought to evaluate changes in fatigue over 1 year in a cohort of chronic inflammatory demyelinating polyneuropathy (CIDP) patients and to correlate changes in fatigue with changes in disability and quality of life. Investigation into other factors that may contribute to fatigue with a particular interest in the role other chronic disease states may play was also performed.METHODS: Fifty patients with CIDP who satisfied the 2010 EFNS/PNS diagnostic criteria were followed over the period of 1 year at three tertiary care centers in Serbia. Assessments of disability, quality of life, and patient perception of change and fatigue were collected at two time points 12 months apart. Comorbidities, treatment regimens, and sedating medication use was collected.RESULTS: Disability, quality of life, and patient perception of change showed statistically significant correlations with change in fatigue (p < .01). Increased levels of fatigue were noted in patients who used sedating medications (p = .05) and who had a comorbid chronic medical condition (p = .01).INTERPRETATION: Worsening fatigue correlates over time with increased disability and worse quality of life. Fatigue is not specific to CIDP, but is common in many chronic medical conditions and with the use of sedating medications. Our findings support the importance of identifying and supportively managing fatigue in patients with CIDP, but cautions against considering fatigue as a CIDP diagnostic symptom or using fatigue to justify immunotherapy utilization.",

keywords = "chronic inflammatory demyelinating polyneuropathy, fatigue, quality of life, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/complications, Polyneuropathies, Humans, Quality of Life, Fatigue/diagnosis, Chronic Disease",

author = "Gable, {Karissa L.} and Stojan Peric and Lutz, {Michael W.} and Ivo Bozovic and Milutin Petrovic and Aleksandar Stojanov and Ivana Basta and Allen, {Jeffrey A.}",

note = "Funding Information: K. G. was a consultant for Apellis and Medscape. J. A. is a consultant for Argenx, alexion, annexon, Akcea, CSL behring, Johnson & Johnson, Grifols, Sanofi, Takeda. S. P. reports the following: he has received lecture honoraria from Pfizer, Viatris, Teva Actavis, Berlin Chemie Menarini, Mylan, Worwag, Adoc and Salveo; research grants from Kedrion, Octapharma and Argenx; consultant fees from Argenx, Mylan and Roche; and travel grants from Octapharma, Kedrion, Teva Actavis, Sanofi Genzyme, Pfizer, Roche, Adoc and Berlin Chemie Menarini. The remaining authors have no disclosures to report. Publisher Copyright: {\textcopyright} 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.",

year = "2022",

month = aug,

doi = "10.1002/brb3.2712",

language = "English (US)",

volume = "12",

journal = "Brain and Behavior",

issn = "2157-9032",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy

AU - Gable, Karissa L.

AU - Peric, Stojan

AU - Lutz, Michael W.

AU - Bozovic, Ivo

AU - Petrovic, Milutin

AU - Stojanov, Aleksandar

AU - Basta, Ivana

AU - Allen, Jeffrey A.

N1 - Funding Information: K. G. was a consultant for Apellis and Medscape. J. A. is a consultant for Argenx, alexion, annexon, Akcea, CSL behring, Johnson & Johnson, Grifols, Sanofi, Takeda. S. P. reports the following: he has received lecture honoraria from Pfizer, Viatris, Teva Actavis, Berlin Chemie Menarini, Mylan, Worwag, Adoc and Salveo; research grants from Kedrion, Octapharma and Argenx; consultant fees from Argenx, Mylan and Roche; and travel grants from Octapharma, Kedrion, Teva Actavis, Sanofi Genzyme, Pfizer, Roche, Adoc and Berlin Chemie Menarini. The remaining authors have no disclosures to report. Publisher Copyright: © 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.

PY - 2022/8

Y1 - 2022/8

N2 - BACKGROUND AND AIMS: Fatigue is a common but poorly understood complaint in patients with immune-mediated polyneuropathies. We sought to evaluate changes in fatigue over 1 year in a cohort of chronic inflammatory demyelinating polyneuropathy (CIDP) patients and to correlate changes in fatigue with changes in disability and quality of life. Investigation into other factors that may contribute to fatigue with a particular interest in the role other chronic disease states may play was also performed.METHODS: Fifty patients with CIDP who satisfied the 2010 EFNS/PNS diagnostic criteria were followed over the period of 1 year at three tertiary care centers in Serbia. Assessments of disability, quality of life, and patient perception of change and fatigue were collected at two time points 12 months apart. Comorbidities, treatment regimens, and sedating medication use was collected.RESULTS: Disability, quality of life, and patient perception of change showed statistically significant correlations with change in fatigue (p < .01). Increased levels of fatigue were noted in patients who used sedating medications (p = .05) and who had a comorbid chronic medical condition (p = .01).INTERPRETATION: Worsening fatigue correlates over time with increased disability and worse quality of life. Fatigue is not specific to CIDP, but is common in many chronic medical conditions and with the use of sedating medications. Our findings support the importance of identifying and supportively managing fatigue in patients with CIDP, but cautions against considering fatigue as a CIDP diagnostic symptom or using fatigue to justify immunotherapy utilization.

AB - BACKGROUND AND AIMS: Fatigue is a common but poorly understood complaint in patients with immune-mediated polyneuropathies. We sought to evaluate changes in fatigue over 1 year in a cohort of chronic inflammatory demyelinating polyneuropathy (CIDP) patients and to correlate changes in fatigue with changes in disability and quality of life. Investigation into other factors that may contribute to fatigue with a particular interest in the role other chronic disease states may play was also performed.METHODS: Fifty patients with CIDP who satisfied the 2010 EFNS/PNS diagnostic criteria were followed over the period of 1 year at three tertiary care centers in Serbia. Assessments of disability, quality of life, and patient perception of change and fatigue were collected at two time points 12 months apart. Comorbidities, treatment regimens, and sedating medication use was collected.RESULTS: Disability, quality of life, and patient perception of change showed statistically significant correlations with change in fatigue (p < .01). Increased levels of fatigue were noted in patients who used sedating medications (p = .05) and who had a comorbid chronic medical condition (p = .01).INTERPRETATION: Worsening fatigue correlates over time with increased disability and worse quality of life. Fatigue is not specific to CIDP, but is common in many chronic medical conditions and with the use of sedating medications. Our findings support the importance of identifying and supportively managing fatigue in patients with CIDP, but cautions against considering fatigue as a CIDP diagnostic symptom or using fatigue to justify immunotherapy utilization.

KW - chronic inflammatory demyelinating polyneuropathy

KW - fatigue

KW - quality of life

KW - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/complications

KW - Polyneuropathies

KW - Humans

KW - Quality of Life

KW - Fatigue/diagnosis

KW - Chronic Disease

UR - http://www.scopus.com/inward/record.url?scp=85134548825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134548825&partnerID=8YFLogxK

U2 - 10.1002/brb3.2712

DO - 10.1002/brb3.2712

M3 - Article

C2 - 35862228

AN - SCOPUS:85134548825

SN - 2157-9032

VL - 12

JO - Brain and Behavior

JF - Brain and Behavior

IS - 8

M1 - e2712

ER -

A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this